C4 Therapeutics (CCCC)
(Delayed Data from NSDQ)
$5.38 USD
+0.04 (0.75%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $5.23 -0.15 (-2.79%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth B Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
CCCC 5.38 +0.04(0.75%)
Will CCCC be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for CCCC based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CCCC
C4 Therapeutics, Inc. (CCCC) Reports Q2 Loss, Tops Revenue Estimates
Community Health Systems (CYH) Reports Q2 Loss, Tops Revenue Estimates
CCCC: What are Zacks experts saying now?
Zacks Private Portfolio Services
C4 Therapeutics (CCCC) Soars 13.7%: Is Further Upside Left in the Stock?
C4 Therapeutics (CCCC) Upgraded to Buy: Here's Why
C4 Therapeutics, Inc. (CCCC) Reports Q4 Loss, Misses Revenue Estimates
Other News for CCCC
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Stifel Nicolaus Keeps Their Buy Rating on C4 Therapeutics (CCCC)
Cautious Hold Rating on C4 Therapeutics Amid Modest Efficacy and Pending Data
Hold Rating on C4 Therapeutics Amid Early-Stage Drug Development and Market Caution
C4 Therapeutics Presents Monotherapy Data Demonstrating Proof of Mechanism and Early Evidence of Proof of Concept From Ongoing CFT1946 Phase 1 Trial in BRAF V600 Mutant Solid Tumors at the European Society for Medical Oncology (ESMO) Congress 2024